Aarey Drugs & Pharmaceuticals share news, announcements and annual reports
NSE: AAREYDRUGSBSE: 524412Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 27 Oct 2026. Previous close ₹103.19.
27 Oct: open ₹100.13, high ₹106.95, low ₹100.13
- Under NSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹340 Cr2,366th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,56,56052.8% delivered
Aarey Drugs & Pharmaceuticals has 183 announcements on record, routine notices left out; 8 in the 30 days to 28 Oct 2026, the latest on 7 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Aarey Drugs & Pharmaceuticals quarterly results
The board met on 14 Aug 2026 to consider financial results
Notice filed 7 Aug 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Aarey Drugs & Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Aarey Drugs & Pharmaceuticals financials, year by year
Annual reports6
- Annual report, year to Mar 20268 Sep 2026
- Annual report, year to Mar 20256 Sep 2025
- Annual report, year to Mar 20246 Sep 2024
- Annual report, year to Mar 202312 Aug 2023, a zip file
- Annual report, year to Mar 20227 Sep 2022, a zip file
1 earlier report
- Annual report, year to Mar 202120 Aug 2021, a zip file
Aarey Drugs & Pharmaceuticals share news and announcements
Newest first. Page 1 of 4.
Oct 2026
7 Oct
3 Oct · Disclosure of material issue
3 Oct · Disclosure of material issue
3 Oct · Disclosure of material issue
Sep 2026
30 Sep · Meeting
30 Sep · Board meeting
30 Sep · Board meeting
5 Sep · Board meeting
Aug 2026
14 Aug · Results
7 Aug · Board meeting
6 Aug · Board meeting
Jul 2026
May 2026
30 May · Results
25 May · Board meeting
Not held on this date
Mar 2026
12 Mar · Legal
Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
Feb 2026
12 Feb · Updates
11 Feb · Results
4 Feb · Board meeting
Nov 2025
13 Nov · Results
Oct 2025
Sep 2025
29 Sep · Meeting
4 Sep · Board meeting
3 Sep · Board meeting
Aug 2025
13 Aug · Results
Jul 2025
Jun 2025
3 Jun
May 2025
30 May · Board meeting
30 May · Results
23 May · Board meeting
22 May · Board meeting
22 May · Board meeting
Not held on this date
8 May
Apr 2025
9 Apr · Legal
The exchange asked on 7 Apr 2025
Mar 2025
Feb 2025
17 Feb · Results
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 17 Aug 2026Resultsup 2.04%+2.2 pts vs Nifty 500market median −0.7% · five sessions −3.2% (−2.9 pts vs Nifty 500) · volume 2.1× usual · The announcement
- 1 Jun 2026Resultsdown 0.80%+0.2 pts vs Nifty 500market median −0.7% · five sessions −0.2% (+0.7 pts vs Nifty 500) · volume 0.7× usual · The announcement
- 12 Feb 2026Resultsup 4.37%+4.9 pts vs Nifty 500market median −0.7% · five sessions +4.9% (+5.4 pts vs Nifty 500) · volume 2.8× usual · delivery +2.3 pts against usual · The announcement
- 14 Aug 2025Resultsup 2.00%+2.1 pts vs Nifty 500market median −0.7% · five sessions +0.1% (−1.9 pts vs Nifty 500) · volume 1.1× usual · The announcement
- 2 Jan 2025Board or managers changedup 1.62%+0.1 pts vs Nifty 500market median 0.0% · five sessions +0.6% (+1.7 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 5 Dec 2024Board or managers changeddown 2.01%−2.8 pts vs Nifty 500market median 0.0% · five sessions −4.2% (−5.3 pts vs Nifty 500) · volume 1.0× usual · The announcement
- 12 Nov 2023Resultsup 1.09%+0.5 pts vs Nifty 500market median −0.7% · five sessions −6.7% (−8.7 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 14 Aug 2023Resultsdown 3.84%−3.6 pts vs Nifty 500market median −0.7% · five sessions −1.8% (−1.8 pts vs Nifty 500) · volume 0.6× usual · The announcement
- 16 Aug 2022Resultsdown 4.22%−5.1 pts vs Nifty 500market median −0.7% · five sessions −4.9% (−4.0 pts vs Nifty 500) · volume 1.6× usual · delivery −3.7 pts against usual · The announcement
- 8 Feb 2022Resultsdown 7.01%−6.9 pts vs Nifty 500market median −0.7% · five sessions −15.3% (−12.2 pts vs Nifty 500) · volume 0.9× usual · delivery −2.8 pts against usual · The announcement
Aarey Drugs & Pharmaceuticals results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Total comprehensive income | Quarter to Dec 2025 | Standalone | 1.28 | 0.57 | −55.4% | 11 Feb 2026 | 11 Apr 2026 |
| Total comprehensive income | Year to date to Dec 2025 | Standalone | 5.30 | 2.96 | −44.1% | 11 Feb 2026 | 11 Apr 2026 |
| Profit before tax | Year to date to Dec 2025 | Standalone | 4.13 | 4.13 | 0.0% | 11 Feb 2026 | 11 Apr 2026 |
| Current tax | Year to date to Dec 2025 | Standalone | −1.07 | 1.07 | +200.0% | 11 Feb 2026 | 11 Apr 2026 |
| Net profit from continuing businesses | Quarter to Dec 2025 | Standalone | 1.28 | 0.57 | −55.4% | 11 Feb 2026 | 11 Apr 2026 |
| Profit before one-off items and tax | Quarter to Dec 2025 | Standalone | 0.92 | 0.92 | 0.0% | 11 Feb 2026 | 11 Apr 2026 |
| Other expenses | Quarter to Dec 2025 | Standalone | 1.00 | 1.00 | 0.0% | 11 Feb 2026 | 11 Apr 2026 |
| Net profit | Year to date to Dec 2025 | Standalone | 5.30 | 2.96 | −44.1% | 11 Feb 2026 | 11 Apr 2026 |
| Profit before tax | Quarter to Dec 2025 | Standalone | 0.92 | 0.92 | 0.0% | 11 Feb 2026 | 11 Apr 2026 |
| Net profit from continuing businesses | Year to date to Dec 2025 | Standalone | 5.30 | 2.96 | −44.1% | 11 Feb 2026 | 11 Apr 2026 |